In this piece we will look at the 5 Best Rising Penny Stocks to Buy According to Wall Street Analysts. Please visit 9 Best Rising Penny Stocks to Buy According to Wall Street Analysts if you’d like to see an extended list and how we came up with the list of Best Rising Penny Stocks to Buy According to Wall Street Analysts.
5. Pacific Biosciences of California, Inc. (NASDAQ:PACB)
One Month Performance: 12.24%
Number of Hedge Fund Holders: 30
Analyst Upside Potential: 59.09%
Pacific Biosciences of California, Inc. (NASDAQ:PACB) has gained more than 12% over the past month and roughly 35% since the global launch of SPRQ-Nx sequencing chemistry. Wall Street expects more than 59% upside from the current level, making it one of the Best Rising Penny Stocks to Buy According to Wall Street Analysts.
Stocks
Pacific Biosciences of California, Inc. (NASDAQ:PACB) on May 26 launched SPRQ-Nx, a new sequencing chemistry for its Revio HiFi platform. Management noted that one of the key benefits of the new sequencing chemistry is cost, as genome sequencing drops to a list price of $345, with the potential to go below $300 at scale. This reflects a 30% reduction from the previous chemistry.
Moreover, management also highlighted a key innovation, which is a reusable SMRT Cell consumable, suggesting that the same physical component can be used multiple times, directly cutting costs. Notably, beta testing across more than 1,400 runs at 20 sites worldwide showed higher yields and lower failure rates compared to the prior version.
The company also upgraded its AI-powered accuracy tool, DeepConsensus. The tool has been developed in partnership with Google, and the updates enabled by Google’s AlphaEvolve coding agent improve both speed and data quality. The company also plans to bring the chemistry to its smaller Vega benchtop system later in 2026.
Pacific Biosciences of California, Inc. (NASDAQ:PACB) is a firm that develops, manufactures, and markets advanced sequencing solutions for genetic analysis. It operates through America, Europe, the Middle East, and Africa, and Asia Pacific segments.
4. MannKind Corporation (NASDAQ:MNKD)
One Month Performance: 13.74%
Number of Hedge Fund Holders: 25
Analyst Upside Potential: 69.08%
MannKind Corporation (NASDAQ:MNKD) is one of the Best Rising Penny Stocks to Buy According to Wall Street Analysts. Recently, on June 23, MannKind Corporation (NASDAQ:MNKD) announced receiving a grant from Breakthrough T1D, which is a leading type 1 diabetes research organization.
The grant is to support the INHALE-1ST clinical trial evaluating inhaled insulin in newly diagnosed pediatric patients. The stock has gained more than 4% since the release and around 13% over the past month.
Management noted that the trial in question focuses on Afrezza, the company’s inhaled insulin product, used alongside a daily injectable basal insulin in patients aged 10 to 17 who have recently been diagnosed with type 1 diabetes. The study aims to assess both safety and efficacy in this younger population.
The grant reflects external validation of Afrezza’s potential and builds on a recent FDA approval allowing Afrezza’s use in children as young as six. The insulin works by delivering insulin through the lungs at mealtime using the company’s Technosphere platform, enabling rapid absorption that closely mimics the body’s natural insulin response. Management noted that if the new product is successful, it can open a new market for the company.
MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company that specializes in chronic disease care. Incorporated in 1991, the company provides solutions for serious conditions, such as diabetes, pulmonary hypertension, and fluid overload.
3. ECARX Holdings Inc. (NASDAQ:ECX)
One Month Performance: 11.43%
Number of Hedge Fund Holders: 21
Analyst Upside Potential: 156.32%
ECARX Holdings Inc. (NASDAQ:ECX) is one of the Best Rising Penny Stocks to Buy According to Wall Street Analysts. Recently, on June 22, ECARX Holdings Inc. (NASDAQ:ECX) announced entering into a definitive agreement to acquire the entire Flyme software business, including Flyme Auto and Flyme OS. The deal is worth $266 million (RMB 1.8 billion). The stock has gained more than 17% since the announcement.
Management noted that Flyme Auto is already running in over 2 million ECARX-powered vehicles, making this an acquisition of technology the company already relies on heavily. Moreover, Flyme OS brings over 15 years of development history that spans smartphones, wearables, and vehicles.
Notably, the deal is structured as a clean carve-out from DreamSmart Group, with all key IP, R&D teams, OEM contracts, and engineering resources transferring to ECARX within six months of closing. Moreover, the financing is split roughly 70% through Chinese bank loans and 30% from internal sources. ECARX will also inject an additional RMB 200 million post-closing to support operations.
The acquisition is expected to enable the company to compete more aggressively in the fast-growing in-car intelligence market.
ECARX Holdings Inc. (NASDAQ:ECX) is an automotive technology company focusing on the automotive sector’s shift towards software-defined vehicles, especially in the electric vehicle and intelligent car markets.
2. C4 Therapeutics, Inc. (NASDAQ:CCCC)
One Month Performance: 16.39%
Number of Hedge Fund Holders: 34
Analyst Upside Potential: 158.22%
C4 Therapeutics, Inc. (NASDAQ:CCCC) has gained roughly 16% over the past month, mainly driven by positive phase 1 clinical trial data for Cemsidomide. The data was presented on June 11, following which the stock rose more than 13%. The Street expects more than 158% upside from the current level, making C4 one of the Best Rising Penny Stocks to Buy According to Wall Street Analysts.
Cemsidomide is C4 Therapeutics, Inc. (NASDAQ:CCCC)’s oral drug candidate for relapsed/refractory multiple myeloma, and the data from the phase 1 trial were presented at the European Hematology Association 2026 Congress. Management noted that the drug targets IKZF1, which is a foundational approach in myeloma treatment that also stimulates immune function.
The data presented covered 73 heavily pretreated patients. Management noted that at the highest dose the drug achieved a 53% overall response rate, a strong result in such a difficult-to-treat population. Notably, responses deepened over time as several patients improved from partial responses to deeper responses, including two achieving MRD negativity. Moreover, the drug was also generally well tolerated, and no discontinuations were recorded.
C4 Therapeutics Inc. (NASDAQ:CCCC) is a clinical-stage biopharmaceutical company that is involved in developing novel targeted protein degradation (TPD) therapies.
1. Angel Studios, Inc. (NYSE:ANGX)
One Month Performance: 13.43%
Number of Hedge Fund Holders: 10
Analyst Upside Potential: 164.80%
Angel Studios, Inc. (NYSE:ANGX) has gained more than 13% over the past month, and the Street expects more than 164.8% upside over the next 12-months. Angel Studios, Inc. (NYSE:ANGX) among our Best Rising Penny Stocks to Buy According to Wall Street Analysts.
The gains have been driven by the strong momentum from Q1 2026 earnings and membership growth. The company released its fiscal Q1 2026 earnings on May 1. During the quarter, the revenue reached $115.11 million, ahead of the expected $106.78 million. Moreover, although the EPS was negative $0.05 (or -$0.08 GAAP), it exceeded the expected negative $0.12 mark.
Angel Studios, Inc. (NYSE:ANGX) is built on a unique model that allows Guild members to vote on which films and TV shows get distributed on the platform. On June 11, the company announced adding nearly 200,000 new Guild members since Q1 2026 earnings. This brings the company’s total to nearly 2.4 million. Moreover, the company also added two new features to its platform, including the Guild Age Rating and Guild Theater Seating. The age rating feature allows members to select age recommendations for new titles, while the theater seating will allow members to see and sit near fellow Guild members when buying movie tickets through the Angel app.
Angel Studios Inc. (NYSE:ANGX) is a community-driven film studio and streaming platform that lets audiences fund, choose, and distribute family-friendly movies and shows, often with faith-based or positive themes, by leveraging equity crowdfunding and its “Angel Guild” to bypass traditional Hollywood gatekeepers.
While we acknowledge the potential of ANGX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ANGX and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 Good Stocks to Invest in Now and 10 Most Undervalued US Stocks According to Hedge Funds.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
